Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | METAP2 | P50579 | 4/20 | 0.65 |
| ▸ | CCR2 | P41597 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3512984 | 0.93 | CYP2C9 (0.90) | CYP2C9CYP1A2CYP2C19METAP2CCR2 | |
| SCHEMBL3514007 | 0.90 | CYP2C9 (0.64) | CYP2C9CYP1A2CYP2C19METAP2LMNA | |
| SCHEMBL3513665 | 0.88 | CYP2C9 (0.82) | CYP2C9CYP1A2CYP2C19METAP2CCR2 | |
| SCHEMBL5955445 | 0.87 | CYP2C9 (0.84) | CYP2C9CYP1A2CYP2C19METAP2LMNA | |
| SCHEMBL13034761 | 0.87 | CYP2C9 (0.84) | CYP2C9CYP1A2CYP2C19METAP2GFER | |
| SCHEMBL3514696 | 0.86 | CYP2C9 (0.79) | CYP2C9CYP1A2CYP2C19METAP2GFER | |
| SCHEMBL3513101 | 0.86 | CYP2C9 (0.79) | CYP2C9CYP1A2CYP2C19METAP2CCR2 | |
| SCHEMBL3513537 | 0.86 | CYP2C9 (0.79) | CYP2C9CYP1A2CYP2C19METAP2CCR2 | |
| SCHEMBL3514014 | 0.85 | CYP2C9 (0.77) | CYP2C9CYP1A2CYP2C19METAP2CCR2 | |
| SCHEMBL13034782 | 0.85 | CYP2C9 (0.77) | CYP2C9CYP1A2CYP2C19METAP2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-11-04 | — | — | US | disclosed |
| WO-2007113337-A1 | A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | C1QBP, CD4, CHRM4 | CYP2C9 4489/4885CYP1A2 4221/4885CYP2C19 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.